Healthcare
Live Price
Offline$1.55
+0.00% today
1Y Change
-52.45%
Window
Jun 26, 2025 → Jun 15, 2026
Coverage: 249 bars · Jun 26, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
InnoCare Pharma Limited (INCPF) is a Healthcare stock with a market cap of $18.01B and listed on OTC. The stock last traded around $1.55 and down 52.5% across the available one-year price window (Jun 26, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +127.6%, EPS growth of +238.5%, a dividend yield of 0.0%. What stands out right now is revenue +127.6%, EPS +238.5%, free cash flow +129.5% with operating margin 23.7% and ROIC 6.2%. Valuation sits in the middle of the pack at P/E 29.5 and price/sales 7.2. Stock Foundry combines INCPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INCPF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INCPF Max Drawdown
-52.45%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for INCPF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.0B
+66.8% YoY
FY Net Income
-$64.5M
+92.7% YoY
Free Cash Flow
-$11.0K
+100.0% YoY
Revenue Growth
+127.6%
EPS Growth
+238.5%
Gross Margin
90.4%
Net Margin
28.8%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.3B | 1.0B | 739M | 625M | 1.0B |
| Gross Profit | 2.0B | 871M | 610M | 482M | 977M |
| Operating Income | 441M | -526M | -651M | -770M | -181M |
| EBITDA | 556M | -313M | -517M | -808M | -167M |
| Net Income | 626M | -441M | -631M | -887M | -65M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.1B | 6.2B | 8.2B | 8.7B | 5.9B |
| Total Assets | 10.8B | 9.4B | 9.9B | 10.3B | 7.4B |
| Total Liabilities | 2.8B | 2.7B | 2.7B | 2.7B | 1.7B |
| Shareholder Equity | 7.7B | 6.7B | 7.1B | 7.6B | 5.6B |
| Total Debt | 1.6B | 1.3B | 1.3B | 1.3B | 1.3B |
| Net Debt | -5.5B | -5.0B | -6.9B | -7.4B | -4.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
167M
+129.5% YoY
Capital Expenditures
167M
+54.9% YoY
Free Cash Flow
11K
+100.0% YoY
Key ratios
Gross Margin
90.4%
Operating Margin
23.7%
Net Margin
28.8%
ROE
10.1%
Debt / Equity
0.25x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.